Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer

• Published in: European journal of surgical oncology Vol. 49; no. 7; pp. 1283 - 1290
• Main Authors: Hofste, Lisa S.M., Geerlings, Maartje J., von Rhein, Daniel, Rütten, Heidi, Westenberg, A. Helen, Weiss, Marjan M., Gilissen, Christian, Hofste, Tom, van der Post, Rachel S., Klarenbeek, Bastiaan R., de Wilt, Johannes H.W., Ligtenberg, Marjolijn J.L., Garms, Linda, Liem, Maite, Rozema, Tom, Wasowicz, Dareczka, Burger, Pim, Polat, Fatih, Reijnders, Koen, de Roos, Marnix, Sietses, Colin
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2023
• Subjects: Chemoradiotherapy; Circulating tumor DNA; Circulating Tumor DNA - genetics; Humans; Liquid biopsies; Neoadjuvant Therapy; Neoadjuvant treatment; Next-generation sequencing; Rectal cancer; Rectal Neoplasms - genetics; Rectal Neoplasms - therapy; Rectum - pathology; Next-generation sequencing; Rectal cancer; cfDNA; CI; Liquid biopsies; HR; VAF; NGS; Circulating tumor DNA; Neoadjuvant treatment; CEA; ctDNA
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2023.01.026

Patients with early-stage and locally advanced rectal cancer are often treated with neoadjuvant therapy followed by surgery or watch and wait. This study evaluated the role of circulating tumor DNA (ctDNA) to measure disease after neoadjuvant treatment and surgery to optimize treatment choices. Patients with rectal cancer treated with both chemotherapy and radiotherapy were included and diagnostic biopsies were analyzed for tumor-specific mutations. Presence of ctDNA was measured in plasma by tracing the tumor-informed mutations using a next-generation sequencing panel. The association between ctDNA detection and clinicopathological characteristics and progression-free survival was measured. Before treatment ctDNA was detected in 69% (35/51) of patients. After neoadjuvant therapy ctDNA was detected in only 15% (5/34) of patients. In none of the patients with a complete clinical response who were selected for a watch and wait strategy (0/10) or patients with ypN0 disease (0/8) ctDNA was detected, whereas it was detected in 31% (5/16) of patients with ypN + disease. After surgery ctDNA was detected in 16% (3/19) of patients, of which all (3/3) developed recurrent disease compared to only 13% (2/16) in patients with undetected ctDNA after surgery. In an exploratory survival analysis, both ctDNA detection after neoadjuvant therapy and after surgery was associated with worse progression-free survival (p = 0.01 and p = 0.007, respectively, Cox-regression). These data show that in patients with early-stage and locally advanced rectal cancer tumor-informed ctDNA detection in plasma using ultradeep sequencing may have clinical value to complement response prediction after neoadjuvant therapy and surgery.